Lissun, an Indian mental health platform, has raised $1.3 million in seed funding in a round led by Inflection Point Ventures and Rainmatter Capital. The startup plans to use the funds to enhance and expand its offerings and services and pursue more partnerships. Taurean Surgical, another Indian startup, secured undisclosed pre-seed funding to deliver its AI-powered robot-assisted 3D surgical microscope to underserved regions. Meanwhile, AI imaging solution provider DeepTek received approval from the Thai Food and Drug Administration for its AI-enabled chest x-ray screening software, Genki. Alveofit obtained FDA approval in the United States for its IoT-based spirometer, Alveoair, positioning it for global expansion.
Lissun scores $1.3 million seed funding
Lissun, a mental health platform from India, has collected $1.3 million in seed funding from a round led by Inflection Point Ventures and Rainmatter Capital.
The startup aims to tackle the stigma around mental health by offering consumer-facing solutions through healthcare institutions in a B2H2C model.
Want to publish your own articles on DistilINFO Publications?
Send us an email, we will get in touch with you.
According to a press statement, Lissun plans to use its fresh funds to enhance and expand its offerings and services, as well as pursue more partnerships.
This funding raise follows the pre-seed round where it raised $1 million last year.
Taurean Surgical bags pre-seed funding to power robotic surgery outside major cities
Another Indian startup, Taurean Surgical, has also raised undisclosed pre-seed funding from Beyond Tech VC, investor Durga Devi Maganti, and American investors.
Using its fresh funds, the company will deliver its AI-powered robot-assisted 3D surgical microscope to underserved regions needing cutting-edge surgical technology. The microscope provides an integrated computer vision, ML, and augmented reality capability to assist surgeons during complex procedures.
“We envision a future where every surgeon, regardless of their geographical location, can leverage the advantages of robotic surgery to provide optimal patient outcomes,” Taurean Surgical CEO and founder Dr Rahul Kumar said in a statement.
Thai FDA clears DeepTek’s AI CXR solution
AI imaging solution provider DeepTek has received the approval of the Thai Food and Drug Administration for its AI-enabled chest x-ray screening software.
Powered by AI, Genki provides automated interpretation of chest x-rays. It is capable of analysing over 19 chest pathologies, including tuberculosis, pneumonia, lung cancer, and chronic pulmonary diseases.
The solution has been used in TB-free initiatives across India, screening over 300,000 individuals to date and raising the nation’s TB detection rate.
DeepTek is now in talks with major medical institutions in Thailand to integrate its AI solutions into their radiology workflows.
“Thailand has gained a reputation for offering excellent medical resources and healthcare services by thinking ahead of time. The recent approval from the Thai regulatory body testifies to the readiness of the country to adopt AI into their healthcare services…We look forward to tapping vast opportunities in Thailand and beyond,” DeepTek co-founder Ajit Patil said about their latest regulatory win.
Alveofit set for global expansion of its IoT-based spirometer
Alveofit also obtained FDA approval in the United States for its IoT-based spirometer, Alveoair.
Based on a press statement, this regulatory approval, along with its strategic partnerships, places the company for further international expansion. Earlier this year, Alveofit opened an office in New York.
Source: MobihealthNews
